Event details
Aeris Environmental (ASX:AEI)
Peter Bush - CEO
Aeris develops, manufactures and markets proprietary, environmentally-friendly technology that drives measurable improvements in asset performance and sustainability.
Atomo Diagnostics (ASX:AT1)
John Kelly - Managing Director
Atomo is a specialist medtech device developer supplying unique and proven rapid diagnostic test devices.
Uscom (ASX:UCM)
Prof Rob Phillips - Chairman & CEO
Uscom is an innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices.
Micro-X (ASX:MX1)
Peter Rowland - Managing Director
A hi-tech company developing and commercialising a range of innovative products for the global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology.
Visioneering Technologies (ASX:VTI)
Dr Stephen Snowdy - CEO
Redefining vision through revolutionary solutions for presbyopia, myopia and astigmatism.
Opthea Limited (ASX:OPT)
Dr Megan Baldwin - CEO & Managing Director
Committed to improving vision in patients suffering from retinal eye diseases.
Pharmaxis (ASX:PXS)
Gary Phillips - CEO
Pharmaceutical research company focussed on inflammation and fibrosis with a portfolio of products at various stages of development and approval.
LBT Innovations (ASX:LBT)
Brent Barnes - Managing Director
LBT Innovations (LBT) is a groundbreaking designer of advanced technology solutions, using artificial intelligence for the medical industry. Based in Adelaide, South Australia, LBT have a history of developing world leading products for microbiology automation and is in the early stages of commercialisation for its technology the APAS®Independence.
Emerald Clinics (ASX:EMD)
Dr Michael Winlo - Managing Director
Operates a network of specialist medical clinics and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients to create robust and ethically-sourced evidence.
Invex Therapeutics (ASX:IXC)
Dr Jason Loveridge - Non-Executive Chairman
Invex is focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions.
